Evidence map›Paper›PMID 36182040›Full record

ArticlePharmacological research2022

Pharmacological targeting of G protein-coupled receptor heteromers.

Estefanía Moreno, Nil Casajuana-Martin, Michael Coyle, Baruc Campos Campos, Ewa Galaj, Claudia Llinas Del Torrent, Arta Seyedian, William Rea, Ning-Sheng Cai, Alessandro Bonifazi and 8 more

Open access · hybridAbstract read
In one paragraph

Article in Pharmacological research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Modulation of DBiomedicines · 2024
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 2 countries.

Estefanía MorenoLaboratory of Molecular Neuropharmacology, Department of Biochemistry and Molecular Biomedicine, Faculty of Biology and Institute of Biomedicine, University of Barcelona, Barcelona, Spain.
Nil Casajuana-MartinLaboratory of Computational Medicine, Biostatistics Unit, Faculty of Medicine, Autonomous University of Barcelona, Bellaterra, Spain.
Michael CoyleBehavioral Neuroscience Program, Department of Psychology, Binghamton University, 4400 Vestal Parkway East, Binghamton, NY, USA.
Baruc Campos CamposIntegrative Neurobiology Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, MD, USA; Center for Research and Advanced Studies, Department of Physiology, Biophysics, and Neurosciences, Mexico City, Mexico.
Ewa GalajAddiction Biology Unit, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, MD, USA.
Claudia Llinas Del TorrentLaboratory of Computational Medicine, Biostatistics Unit, Faculty of Medicine, Autonomous University of Barcelona, Bellaterra, Spain.
Arta SeyedianIntegrative Neurobiology Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, MD, USA.
William ReaIntegrative Neurobiology Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, MD, USA.
Ning-Sheng CaiIntegrative Neurobiology Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, MD, USA.
Alessandro BonifaziMedicinal Chemistry Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, MD, USA.
Benjamín FloránCenter for Research and Advanced Studies, Department of Physiology, Biophysics, and Neurosciences, Mexico City, Mexico.
Zheng-Xiong XiAddiction Biology Unit, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, MD, USA.
Xavier GuitartIntegrative Neurobiology Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, MD, USA.
Vicent CasadóLaboratory of Molecular Neuropharmacology, Department of Biochemistry and Molecular Biomedicine, Faculty of Biology and Institute of Biomedicine, University of Barcelona, Barcelona, Spain.
Amy H NewmanMedicinal Chemistry Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, MD, USA.
Christopher BishopBehavioral Neuroscience Program, Department of Psychology, Binghamton University, 4400 Vestal Parkway East, Binghamton, NY, USA. Electronic address: cbishop@binghamton.edu.
Leonardo PardoLaboratory of Computational Medicine, Biostatistics Unit, Faculty of Medicine, Autonomous University of Barcelona, Bellaterra, Spain. Electronic address: leonardo.pardo@uab.cat.
Sergi FerréIntegrative Neurobiology Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, MD, USA. Electronic address: sferre@intra.nida.nih.gov.
National Institute on Drug Abuse · USNational Institutes of Health · USUniversitat Autònoma de Barcelona · ESBinghamton University · USUniversitat de Barcelona · ESCenter for Neurosciences · US

Funding

Neurotransmitter Receptor Heteromers in the Striatal Spine ModuleZIADA000493 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI FERRE, SERGI · 2009 to 2025
$35.6M
Novel Dopamine D3 Receptor Ligands ZIADA000424 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI NEWMAN, AMY HAUCK · 2009 to 2025
$25.9M
Interrogating Maladaptive Serotonin Raphe-Striatal Plasticity in L-DOPA-Induced DyskinesiaR01NS122226 · NINDS · STATE UNIVERSITY OF NY,BINGHAMTON · PI CHRISTOPHER R BISHOP, Fredric Manfredsson · 2022 to 2026
$3.1M
Intramural NIH HHS ZIA DA000424Intramural NIH HHS ZIA DA000493NINDS NIH HHS R01 NS122226
6 · The paper itself

Abstract

A main rationale for the role of G protein-coupled receptor (GPCR) heteromers as targets for drug development is the putative ability of selective ligands for specific GPCRs to change their pharmacological properties upon GPCR heteromerization. The present study provides a proof of concept for this rationale by demonstrating that heteromerization of dopamine D

Indexed as

DyskinesiasLevodopaAnimalsBenzamidesDopamineLigandsMicePiperazinesPyridinesRatsReceptors, Dopamine D1Receptors, Dopamine D3Receptors, G-Protein-CoupledBenzamidesDopamineLevodopaLigandsN-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)but-2-enyl)-4-pyridine-2-ylbenzamideN-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)-4-(pyridin-3-yl)benzamidePiperazinesPyridinesReceptors, Dopamine D1Receptors, Dopamine D3Receptors, G-Protein-CoupledDopamine D(1) receptorDopamine D(3) receptorG protein-coupled receptor (GPCR) heteromersL-DOPA-induced dyskinesiaLocomotor activationMousePG01037 (PubChem CID: 11477180)PG01042 (PubChem CID: 11443078)Pramipexole (PubChem CID: 119570)RatSKF81297 (PubChem CID: 1218)VK4–116 (PubChem CID: 130431318)

Identifiers

PMID36182040
PMCPMC9645299
OpenAlexW4297498917

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.